GENTIBIO
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases. The early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to... successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system. GentiBio is a Seattle, Washington-headquartered company launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker.
GENTIBIO
Industry:
Biotechnology Life Science
Founded:
2020-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.gentibio.com
Total Employee:
1+
Status:
Active
Total Funding:
177 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Wordpress Plugins Nginx Sitelinks Search Box
Similar Organizations
AavantiBio
AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
JDRF T1D Fund
JDRF T1D Fund investment in Series A - GentiBio
Novartis Venture Fund
Novartis Venture Fund investment in Series A - GentiBio
RA Capital Management
RA Capital Management investment in Series A - GentiBio
Avidity Partners
Avidity Partners investment in Series A - GentiBio
Seattle Children's Hospital and Research Institute
Seattle Children's Hospital and Research Institute investment in Series A - GentiBio
Matrix Capital Management
Matrix Capital Management investment in Series A - GentiBio
OrbiMed
OrbiMed investment in Series A - GentiBio
RA Capital Management
RA Capital Management investment in Seed Round - GentiBio
OrbiMed
OrbiMed investment in Seed Round - GentiBio
Novartis Venture Fund
Novartis Venture Fund investment in Seed Round - GentiBio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-01 | GentiBio Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer |
| 2022-02-10 | GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer |
Official Site Inspections
http://www.gentibio.com
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "GentiBio"
GentiBio - Crunchbase Company Profile & Funding
GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or …See details»
About - GentiBio
GentiBio’s Tregs: the future of immunology therapeutics. Our goal is to replace the need for systemic and less selective immune suppressive therapies and their associated risks. …See details»
GentiBio - LinkedIn
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat ...See details»
GentiBio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore GentiBio, Inc. with its drug pipeline, therapeutic area, technology platform, 27 news, and 3 literature, Disease Domain:Endocrinology and Metabolic Disease, Immune System Diseases, …See details»
Our Team - GentiBio
David Rawlings, MD. Director, Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Scientific Co-founder and Senior Scientific AdvisorSee details»
GentiBio Company Profile 2024: Valuation, Funding
When was GentiBio founded? GentiBio was founded in 2020. Where is GentiBio headquartered? GentiBio is headquartered in Cambridge, MA. What is the size of GentiBio? GentiBio has 82 total employees. What industry is GentiBio in? …See details»
GentiBio - Funding, Financials, Valuation & Investors - Crunchbase
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases. Search Crunchbase. ... How much funding has this …See details»
GentiBio - VentureRadar
" GentiBio, Inc., is an emerging biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells programmed to treat …See details»
GentiBio Company Profile - Office Locations, Competitors ... - Craft
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. Its …See details»
GentiBio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. GentiBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... GentiBio has 1 board member or advisor, …See details»
GentiBio Announces $157M Series A Financing to Advance …
BOSTON, MA – August 11, 2021 . GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced it has …See details»
Novartis and a string of high profile backers fund next-gen Treg …
Aug 5, 2020 OrbiMed, Novartis Venture Fund and RA Capital Management have joined forces to fund and help launch GentiBio. The Boston, Massachusetts-based biotech starts life with a …See details»
Company Spotlight: GentiBio - Medium
Sep 9, 2021 GentiBio is an early stage, privately held biotech company, founded in 2020. The company is focused on developing new therapies to regulate aberrantly functioning immune …See details»
Management Archives - GentiBio
Prior to joining GentiBio, Tom was the Director of Automation and Data at Juno Therapeutics where he managed a team that supported both the commercialized Breyanzi and Abecma …See details»
GentiBio Announces $157M Series A Financing to Advance …
Aug 11, 2021 GentiBio, Inc., is an emerging biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells programmed …See details»
GentiBio Launches with $20M Seed Funding from OrbiMed, …
Aug 5, 2020 GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver …See details»
GentiBio and Forge Biologics Announce Viral Vector Contract …
Jul 15, 2021 BOSTON, MA, SEATTLE, WA, and COLUMBUS, OH, July 15, 2021—GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T …See details»
Our Pipeline - GentiBio
Programs to restore immune balance in difficult to treat immune and inflammatory diseasesSee details»
News - GentiBio
Jan 6, 2022 GentiBio Announces Preclinical Data for GNTI-122, GentiBio’s Lead Candidate, an Autologous, Antigen-Specific Engineered T Regulatory Cell (EngTregs) for the Treatment of …See details»